Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings Inc (NQ: HRMY )

33.65 +0.42 (+1.26%)
Streaming Delayed Price Updated: 11:37 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harmony Biosciences Holdings Inc

< Previous 1 2 3 4 5 6 Next >
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
Via Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
The company is focused on developing its pipeline of sleep and epilepsy drugs. 
Via Investor's Business Daily
Earnings Outlook For Harmony Biosciences
Via Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Via Benzinga
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. 
Via Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
Via Benzinga
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Key Takeaways From Harmony Biosciences Analyst Ratings
Via Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Via Benzinga
Analyst Ratings For Harmony Biosciences
Via Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with... 
Via Benzinga
Topics Earnings
Exposures Financial
Updates: HRMY, MELI, SWAV
​​​​​​​Another day, another slew of quarterly update reports for our followed stocks. 
Via Talk Markets
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY. 
Via Chartmill
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently. 
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks. 
Via InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Why Harmony Biosciences Stock Got Slammed Today
The commercial-stage company was dinged by a bearish new take from a researcher. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.